Additionally, activating p53 eliminates CML stem cells.[24] In summary, PMIBcr/Abl‐R6 functions by two pathways: Bcr/Abl and p53. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.